SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters

MLA

C. Fan, et al. “SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters.” Annals of the Rheumatic Diseases, vol. 72, June 2013, p. A620.2-A620. EBSCOhost, https://doi.org/10.1136/annrheumdis-2013-eular.1843.

APA

C. Fan, Allen Radin, Twj Huizinga, Mark C. Genovese, R.M. Fleischmann, & Stefano Fiore. (2013). SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters. Annals of the Rheumatic Diseases, 72, A620.2-A620. https://doi.org/10.1136/annrheumdis-2013-eular.1843

Chicago

C. Fan, Allen Radin, Twj Huizinga, Mark C. Genovese, R.M. Fleischmann, and Stefano Fiore. 2013. “SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters.” Annals of the Rheumatic Diseases 72 (June): A620.2-A620. doi:10.1136/annrheumdis-2013-eular.1843.